Antibiotic treatment of ceftriaxone-susceptible Serratia marcescens bacteremia: A multicenter, retrospective cohort study
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204652 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Abdallah Mughrabi und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Bacteremia, Carbapenems, Ceftriaxone. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Mughrabi, A., Maamari, J., Phillips, T., Alabbasi, A., Brooks, A., Nuriev, R., Zenkin, L., Jaber, B. L., & Nader, C. (2025). Antibiotic treatment of ceftriaxone-susceptible Serratia marcescens bacteremia: A multicenter, retrospective cohort study. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204652
Vancouver
Mughrabi A, Maamari J, Phillips T, Alabbasi A, Brooks A, Nuriev R, et al. Antibiotic treatment of ceftriaxone-susceptible Serratia marcescens bacteremia: A multicenter, retrospective cohort study. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204652
BibTeX
@article{Mughrabi2025,
author = {Mughrabi, Abdallah and Maamari, Julian and Phillips, Timothy and Alabbasi, Afaq and Brooks, Aislinn and Nuriev, Rinat and Zenkin, Lisa and Jaber, Bertrand L and Nader, Claudia},
title = {Antibiotic treatment of ceftriaxone-susceptible Serratia marcescens bacteremia: A multicenter, retrospective cohort study},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204652}
}
EUVIMED